Unmodified official OCDS data retained by Tenderline for this procurement process.
Complete current OCDS release JSON
{
"id": "020567-2025",
"tag": [
"award",
"contract"
],
"bids": {
"statistics": [
{
"id": "19",
"value": 1,
"measure": "bids",
"relatedLot": "1"
},
{
"id": "20",
"value": 1,
"measure": "electronicBids",
"relatedLot": "1"
}
]
},
"date": "2025-05-12T15:18:31+01:00",
"ocid": "ocds-h6vhtk-03a281",
"buyer": {
"id": "GB-FTS-40530",
"name": "The Christie NHS Foundation Trust"
},
"awards": [
{
"id": "020567-2025-1",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-147363",
"name": "SYNLAB"
}
],
"relatedLots": [
"1"
]
}
],
"tender": {
"id": "ocds-h6vhtk-03a281",
"lots": [
{
"id": "1",
"status": "cancelled",
"hasOptions": false,
"description": "The current pathology service provides routine and specialist pathology services with c100 dedicated staff on The Christie Hospital site. The service includes translational biomarker development and supports the Trust’s ambitious Research and Innovation (R&I) programme and clinical trials portfolio.<br/><br/>Demand for testing is increasing year on year reflecting the Trust’s oncology case load. The Trust sought a JV pathology partner who is able to deliver the Trust’s strategic ambitions, including accommodation of projected testing growth demand and flexible options for the development of facilities, estate, technology, and changes in clinical pathways.<br/><br/>Vision<br/>To provide a world leading comprehensive pathology service that supports timely and highquality<br/>delivery of patient care - regionally and nationally - and develops an internationally recognised workforce who, with academic and industry partners, deliver a pioneering<br/>programme of research and innovation.<br/><br/>Principles/Objectives<br/>The Future Pathology Service should reflect the following principles/objectives:<br/><br/>• Safe, effective, and responsive to the diversity of patient and clinical needs and offers the specialist and integrated pathology services needed to support a regional tertiary cancer centre.<br/>• Delivery of a sustainable future pathology workforce<br/>• alignment with the Trust’s Vision and Values and the objectives of Greater Manchester Cancer.<br/>• Commitment to working as part of Greater Manchester ICS in the delivery of the Core20PLUS5 programme to support the reduction of health inequalities at both national and system level.<br/>• Enabled by a strong digital infrastructure and capability. Adopting digital opportunity and technology advances to deliver more efficient and scalable pathology services.<br/>• A service model that considers The Trust’s local, regional national and international partnerships, including engagement with the Greater Manchester Pathology Network to<br/>explore opportunities to support system requirements.<br/>• Delivered through a partnership that has a strategy for profitable growth through expanding test repertoire and customer base.<br/>• Builds upon the Trust’s reputation as an international leader in research and innovation, which is further strengthened by being a partner in the Manchester Cancer Research Centre<br/>(MCRC) and Health Innovation Manchester.<br/>• A service with capital investment to provide best in class facilities.<br/>• A service that has education at its core.<br/><br/>The Future Operating Model for Pathology must include:<br/><br/>• An end-to-end comprehensive pathology service<br/>• Blood sciences including haematology, blood transfusion, clinical biochemistry and immunoassay<br/>• On-site essential services laboratory to support time critical and pathway critical services<br/>• Histopathology (including immunohistochemistry and receptor analysis)<br/>• Stem Cell Laboratory<br/>• Point-of-Care Testing<br/>• A future-proof design with activity growth in service expectation factored in – including expansion of on-site and off-site facilities to meet projected demand;<br/>• An agile approach that can respond to evolving technology and operational requirements and provide improvements to the Trust Pathology Estate;<br/>• Training, Development and Education, Research and Innovation<br/>• Positive workplace culture<br/>• IT infrastructure and digital enablement (including Digital Histopathology)<br/>• Best in class equipment and instrumentation",
"awardCriteria": {
"criteria": [
{
"name": "Clinical / Operational",
"type": "quality",
"description": "13"
},
{
"name": "Quality and Safety",
"type": "quality",
"description": "5"
},
{
"name": "Implementation",
"type": "quality",
"description": "4.8"
},
{
"name": "Future-proofing",
"type": "quality",
"description": "4.8"
},
{
"name": "Research & Innovation",
"type": "quality",
"description": "4.2"
},
{
"name": "Workforce",
"type": "quality",
"description": "8"
},
{
"name": "I&MT",
"type": "quality",
"description": "8"
},
{
"name": "Strategy, Risk & Governance",
"type": "quality",
"description": "7.2"
},
{
"name": "Social Value",
"type": "quality",
"description": "10"
},
{
"name": "Legal",
"type": "quality",
"description": "5"
},
{
"type": "price",
"description": "30"
}
]
}
}
],
"items": [
{
"id": "1",
"relatedLot": "1",
"deliveryAddresses": [
{
"region": "UKD3"
}
],
"additionalClassifications": [
{
"id": "85110000",
"scheme": "CPV",
"description": "Hospital and related services"
},
{
"id": "85111810",
"scheme": "CPV",
"description": "Blood analysis services"
}
]
}
],
"title": "Pathology Service Joint Venture",
"status": "complete",
"coveredBy": [
"GPA"
],
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"description": "The Trust has worked with a commercial partner in a joint venture (JV) arrangement to deliver a comprehensive pathology service for the last 10 years. Building on this knowledge and experience, the Trust was looking for a new partner that matches its ambitions.<br/>The initial term of the pathology service JVwill be for a period of fifteen (15) years with an option to extend by up to five (5) years.<br/>The Trust was looking for a partner that will;<br/>• Provide an exceptional, high-quality service that meets the specialist needs of a<br/>comprehensive cancer centre;<br/>• Provide investment for the provision of world class infrastructure;<br/>• Embrace the exciting opportunities presented with the co-location of a world leading<br/>oncology research centre; and<br/>• Provide expert guidance along with the creativity and drive to deliver a modern, thriving,<br/>truly exceptional pathology service for patients.",
"classification": {
"id": "85111800",
"scheme": "CPV",
"description": "Pathology services"
},
"procurementMethod": "selective",
"mainProcurementCategory": "services",
"procurementMethodDetails": "Competitive dialogue"
},
"parties": [
{
"id": "GB-FTS-40530",
"name": "The Christie NHS Foundation Trust",
"roles": [
"buyer"
],
"address": {
"region": "UKD3",
"locality": "Manchester",
"postalCode": "M20 4BX",
"countryName": "United Kingdom",
"streetAddress": "Wilmslow Road"
},
"details": {
"url": "https://www.christie.nhs.uk/",
"buyerProfile": "https://www.christie.nhs.uk/",
"classifications": [
{
"id": "BODY_PUBLIC",
"scheme": "TED_CA_TYPE",
"description": "Body governed by public law"
},
{
"id": "07",
"scheme": "COFOG",
"description": "Health"
}
]
},
"identifier": {
"legalName": "The Christie NHS Foundation Trust"
},
"contactPoint": {
"name": "Diane Sinclair",
"email": "diane.sinclair@nhs.net",
"telephone": "+44 7748624560"
}
},
{
"id": "GB-FTS-147363",
"name": "SYNLAB",
"roles": [
"supplier"
],
"address": {
"region": "UKI",
"locality": "London",
"postalCode": "SE1 1NA",
"countryName": "United Kingdom",
"streetAddress": "Francis House, 9 King's Head Yard, London."
},
"details": {
"url": "http://www.synlab.co.uk",
"scale": "sme"
},
"identifier": {
"id": "03216065",
"legalName": "SYNLAB"
},
"contactPoint": {
"email": "amy.davenport@synlab.co.uk"
}
},
{
"id": "GB-FTS-1661",
"name": "The High Court",
"roles": [
"reviewBody"
],
"address": {
"locality": "London",
"postalCode": "WC2A 2LL",
"countryName": "United Kingdom",
"streetAddress": "The Strand"
},
"details": {
"url": "https://www.judiciary.uk/courts-and-tribunals/high-court/"
},
"identifier": {
"legalName": "The High Court"
}
}
],
"language": "en",
"contracts": [
{
"id": "020567-2025-1",
"value": {
"amount": 200000000,
"currency": "GBP"
},
"status": "active",
"awardID": "020567-2025-1",
"dateSigned": "2025-05-12T00:00:00+01:00"
}
],
"description": "The proposed contract is to be let for an initial term of 180 months. There is also an option to extend the Contract by up to a further 60 months following the initial term.",
"initiationType": "tender"
}Complete JSON history (8 releases)
12 May 2025 · 020567-2025 · award, contract
{
"id": "020567-2025",
"tag": [
"award",
"contract"
],
"bids": {
"statistics": [
{
"id": "19",
"value": 1,
"measure": "bids",
"relatedLot": "1"
},
{
"id": "20",
"value": 1,
"measure": "electronicBids",
"relatedLot": "1"
}
]
},
"date": "2025-05-12T15:18:31+01:00",
"ocid": "ocds-h6vhtk-03a281",
"buyer": {
"id": "GB-FTS-40530",
"name": "The Christie NHS Foundation Trust"
},
"awards": [
{
"id": "020567-2025-1",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-147363",
"name": "SYNLAB"
}
],
"relatedLots": [
"1"
]
}
],
"tender": {
"id": "ocds-h6vhtk-03a281",
"lots": [
{
"id": "1",
"status": "cancelled",
"hasOptions": false,
"description": "The current pathology service provides routine and specialist pathology services with c100 dedicated staff on The Christie Hospital site. The service includes translational biomarker development and supports the Trust’s ambitious Research and Innovation (R&I) programme and clinical trials portfolio.<br/><br/>Demand for testing is increasing year on year reflecting the Trust’s oncology case load. The Trust sought a JV pathology partner who is able to deliver the Trust’s strategic ambitions, including accommodation of projected testing growth demand and flexible options for the development of facilities, estate, technology, and changes in clinical pathways.<br/><br/>Vision<br/>To provide a world leading comprehensive pathology service that supports timely and highquality<br/>delivery of patient care - regionally and nationally - and develops an internationally recognised workforce who, with academic and industry partners, deliver a pioneering<br/>programme of research and innovation.<br/><br/>Principles/Objectives<br/>The Future Pathology Service should reflect the following principles/objectives:<br/><br/>• Safe, effective, and responsive to the diversity of patient and clinical needs and offers the specialist and integrated pathology services needed to support a regional tertiary cancer centre.<br/>• Delivery of a sustainable future pathology workforce<br/>• alignment with the Trust’s Vision and Values and the objectives of Greater Manchester Cancer.<br/>• Commitment to working as part of Greater Manchester ICS in the delivery of the Core20PLUS5 programme to support the reduction of health inequalities at both national and system level.<br/>• Enabled by a strong digital infrastructure and capability. Adopting digital opportunity and technology advances to deliver more efficient and scalable pathology services.<br/>• A service model that considers The Trust’s local, regional national and international partnerships, including engagement with the Greater Manchester Pathology Network to<br/>explore opportunities to support system requirements.<br/>• Delivered through a partnership that has a strategy for profitable growth through expanding test repertoire and customer base.<br/>• Builds upon the Trust’s reputation as an international leader in research and innovation, which is further strengthened by being a partner in the Manchester Cancer Research Centre<br/>(MCRC) and Health Innovation Manchester.<br/>• A service with capital investment to provide best in class facilities.<br/>• A service that has education at its core.<br/><br/>The Future Operating Model for Pathology must include:<br/><br/>• An end-to-end comprehensive pathology service<br/>• Blood sciences including haematology, blood transfusion, clinical biochemistry and immunoassay<br/>• On-site essential services laboratory to support time critical and pathway critical services<br/>• Histopathology (including immunohistochemistry and receptor analysis)<br/>• Stem Cell Laboratory<br/>• Point-of-Care Testing<br/>• A future-proof design with activity growth in service expectation factored in – including expansion of on-site and off-site facilities to meet projected demand;<br/>• An agile approach that can respond to evolving technology and operational requirements and provide improvements to the Trust Pathology Estate;<br/>• Training, Development and Education, Research and Innovation<br/>• Positive workplace culture<br/>• IT infrastructure and digital enablement (including Digital Histopathology)<br/>• Best in class equipment and instrumentation",
"awardCriteria": {
"criteria": [
{
"name": "Clinical / Operational",
"type": "quality",
"description": "13"
},
{
"name": "Quality and Safety",
"type": "quality",
"description": "5"
},
{
"name": "Implementation",
"type": "quality",
"description": "4.8"
},
{
"name": "Future-proofing",
"type": "quality",
"description": "4.8"
},
{
"name": "Research & Innovation",
"type": "quality",
"description": "4.2"
},
{
"name": "Workforce",
"type": "quality",
"description": "8"
},
{
"name": "I&MT",
"type": "quality",
"description": "8"
},
{
"name": "Strategy, Risk & Governance",
"type": "quality",
"description": "7.2"
},
{
"name": "Social Value",
"type": "quality",
"description": "10"
},
{
"name": "Legal",
"type": "quality",
"description": "5"
},
{
"type": "price",
"description": "30"
}
]
}
}
],
"items": [
{
"id": "1",
"relatedLot": "1",
"deliveryAddresses": [
{
"region": "UKD3"
}
],
"additionalClassifications": [
{
"id": "85110000",
"scheme": "CPV",
"description": "Hospital and related services"
},
{
"id": "85111810",
"scheme": "CPV",
"description": "Blood analysis services"
}
]
}
],
"title": "Pathology Service Joint Venture",
"status": "complete",
"coveredBy": [
"GPA"
],
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"description": "The Trust has worked with a commercial partner in a joint venture (JV) arrangement to deliver a comprehensive pathology service for the last 10 years. Building on this knowledge and experience, the Trust was looking for a new partner that matches its ambitions.<br/>The initial term of the pathology service JVwill be for a period of fifteen (15) years with an option to extend by up to five (5) years.<br/>The Trust was looking for a partner that will;<br/>• Provide an exceptional, high-quality service that meets the specialist needs of a<br/>comprehensive cancer centre;<br/>• Provide investment for the provision of world class infrastructure;<br/>• Embrace the exciting opportunities presented with the co-location of a world leading<br/>oncology research centre; and<br/>• Provide expert guidance along with the creativity and drive to deliver a modern, thriving,<br/>truly exceptional pathology service for patients.",
"classification": {
"id": "85111800",
"scheme": "CPV",
"description": "Pathology services"
},
"procurementMethod": "selective",
"mainProcurementCategory": "services",
"procurementMethodDetails": "Competitive dialogue"
},
"parties": [
{
"id": "GB-FTS-40530",
"name": "The Christie NHS Foundation Trust",
"roles": [
"buyer"
],
"address": {
"region": "UKD3",
"locality": "Manchester",
"postalCode": "M20 4BX",
"countryName": "United Kingdom",
"streetAddress": "Wilmslow Road"
},
"details": {
"url": "https://www.christie.nhs.uk/",
"buyerProfile": "https://www.christie.nhs.uk/",
"classifications": [
{
"id": "BODY_PUBLIC",
"scheme": "TED_CA_TYPE",
"description": "Body governed by public law"
},
{
"id": "07",
"scheme": "COFOG",
"description": "Health"
}
]
},
"identifier": {
"legalName": "The Christie NHS Foundation Trust"
},
"contactPoint": {
"name": "Diane Sinclair",
"email": "diane.sinclair@nhs.net",
"telephone": "+44 7748624560"
}
},
{
"id": "GB-FTS-147363",
"name": "SYNLAB",
"roles": [
"supplier"
],
"address": {
"region": "UKI",
"locality": "London",
"postalCode": "SE1 1NA",
"countryName": "United Kingdom",
"streetAddress": "Francis House, 9 King's Head Yard, London."
},
"details": {
"url": "http://www.synlab.co.uk",
"scale": "sme"
},
"identifier": {
"id": "03216065",
"legalName": "SYNLAB"
},
"contactPoint": {
"email": "amy.davenport@synlab.co.uk"
}
},
{
"id": "GB-FTS-1661",
"name": "The High Court",
"roles": [
"reviewBody"
],
"address": {
"locality": "London",
"postalCode": "WC2A 2LL",
"countryName": "United Kingdom",
"streetAddress": "The Strand"
},
"details": {
"url": "https://www.judiciary.uk/courts-and-tribunals/high-court/"
},
"identifier": {
"legalName": "The High Court"
}
}
],
"language": "en",
"contracts": [
{
"id": "020567-2025-1",
"value": {
"amount": 200000000,
"currency": "GBP"
},
"status": "active",
"awardID": "020567-2025-1",
"dateSigned": "2025-05-12T00:00:00+01:00"
}
],
"description": "The proposed contract is to be let for an initial term of 180 months. There is also an option to extend the Contract by up to a further 60 months following the initial term.",
"initiationType": "tender"
}12 May 2025 · 020560-2025 · award, contract
{
"id": "020560-2025",
"tag": [
"award",
"contract"
],
"bids": {
"statistics": [
{
"id": "17",
"value": 1,
"measure": "bids",
"relatedLot": "1"
},
{
"id": "18",
"value": 1,
"measure": "electronicBids",
"relatedLot": "1"
}
]
},
"date": "2025-05-12T15:08:21+01:00",
"ocid": "ocds-h6vhtk-03a281",
"buyer": {
"id": "GB-FTS-40530",
"name": "The Christie NHS Foundation Trust"
},
"awards": [
{
"id": "020560-2025-1",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-147363",
"name": "SYNLAB"
}
],
"relatedLots": [
"1"
]
}
],
"tender": {
"id": "ocds-h6vhtk-03a281",
"lots": [
{
"id": "1",
"status": "cancelled",
"hasOptions": false,
"description": "The current pathology service provides routine and specialist pathology services with c100 dedicated staff on The Christie Hospital site. The service includes translational biomarker development and supports the Trust’s ambitious Research and Innovation (R&I) programme and clinical trials portfolio.<br/><br/>Demand for testing is increasing year on year reflecting the Trust’s oncology case load. The Trust sought a JV pathology partner who is able to deliver the Trust’s strategic ambitions, including accommodation of projected testing growth demand and flexible options for the development of facilities, estate, technology, and changes in clinical pathways.<br/><br/>Vision<br/>To provide a world leading comprehensive pathology service that supports timely and highquality<br/>delivery of patient care - regionally and nationally - and develops an internationally recognised workforce who, with academic and industry partners, deliver a pioneering<br/>programme of research and innovation.<br/><br/>Principles/Objectives<br/>The Future Pathology Service should reflect the following principles/objectives:<br/><br/>• Safe, effective, and responsive to the diversity of patient and clinical needs and offers the specialist and integrated pathology services needed to support a regional tertiary cancer centre.<br/>• Delivery of a sustainable future pathology workforce<br/>• alignment with the Trust’s Vision and Values and the objectives of Greater Manchester Cancer.<br/>• Commitment to working as part of Greater Manchester ICS in the delivery of the Core20PLUS5 programme to support the reduction of health inequalities at both national and system level.<br/>• Enabled by a strong digital infrastructure and capability. Adopting digital opportunity and technology advances to deliver more efficient and scalable pathology services.<br/>• A service model that considers The Trust’s local, regional national and international partnerships, including engagement with the Greater Manchester Pathology Network to<br/>explore opportunities to support system requirements.<br/>• Delivered through a partnership that has a strategy for profitable growth through expanding test repertoire and customer base.<br/>• Builds upon the Trust’s reputation as an international leader in research and innovation, which is further strengthened by being a partner in the Manchester Cancer Research Centre<br/>(MCRC) and Health Innovation Manchester.<br/>• A service with capital investment to provide best in class facilities.<br/>• A service that has education at its core.<br/><br/>The Future Operating Model for Pathology must include:<br/><br/>• An end-to-end comprehensive pathology service<br/>• Blood sciences including haematology, blood transfusion, clinical biochemistry and immunoassay<br/>• On-site essential services laboratory to support time critical and pathway critical services<br/>• Histopathology (including immunohistochemistry and receptor analysis)<br/>• Stem Cell Laboratory<br/>• Point-of-Care Testing<br/>• A future-proof design with activity growth in service expectation factored in – including expansion of on-site and off-site facilities to meet projected demand;<br/>• An agile approach that can respond to evolving technology and operational requirements and provide improvements to the Trust Pathology Estate;<br/>• Training, Development and Education, Research and Innovation<br/>• Positive workplace culture<br/>• IT infrastructure and digital enablement (including Digital Histopathology)<br/>• Best in class equipment and instrumentation",
"awardCriteria": {
"criteria": [
{
"name": "Clinical / Operational",
"type": "quality",
"description": "13"
},
{
"name": "Quality and Safety",
"type": "quality",
"description": "5"
},
{
"name": "Implementation",
"type": "quality",
"description": "4.8"
},
{
"name": "Future-proofing",
"type": "quality",
"description": "4.8"
},
{
"name": "Research & Innovation",
"type": "quality",
"description": "4.2"
},
{
"name": "Workforce",
"type": "quality",
"description": "8"
},
{
"name": "I&MT",
"type": "quality",
"description": "8"
},
{
"name": "Strategy, Risk & Governance",
"type": "quality",
"description": "7.2"
},
{
"name": "Social Value",
"type": "quality",
"description": "10"
},
{
"name": "Legal",
"type": "quality",
"description": "5"
},
{
"type": "price",
"description": "30"
}
]
}
}
],
"items": [
{
"id": "1",
"relatedLot": "1",
"deliveryAddresses": [
{
"region": "UKD3"
}
],
"additionalClassifications": [
{
"id": "85110000",
"scheme": "CPV",
"description": "Hospital and related services"
},
{
"id": "85111810",
"scheme": "CPV",
"description": "Blood analysis services"
}
]
}
],
"title": "Pathology Service Joint Venture",
"status": "complete",
"coveredBy": [
"GPA"
],
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"description": "The Trust has worked with a commercial partner in a joint venture (JV) arrangement to deliver a comprehensive pathology service for the last 10 years. Building on this knowledge and experience, the Trust was looking for a new partner that matches its ambitions.<br/>The initial term of the pathology service JVwill be for a period of fifteen (15) years with an option to extend by up to five (5) years.<br/>The Trust was looking for a partner that will;<br/>• Provide an exceptional, high-quality service that meets the specialist needs of a<br/>comprehensive cancer centre;<br/>• Provide investment for the provision of world class infrastructure;<br/>• Embrace the exciting opportunities presented with the co-location of a world leading<br/>oncology research centre; and<br/>• Provide expert guidance along with the creativity and drive to deliver a modern, thriving,<br/>truly exceptional pathology service for patients.",
"classification": {
"id": "85111800",
"scheme": "CPV",
"description": "Pathology services"
},
"procurementMethod": "selective",
"mainProcurementCategory": "services",
"procurementMethodDetails": "Competitive dialogue"
},
"parties": [
{
"id": "GB-FTS-40530",
"name": "The Christie NHS Foundation Trust",
"roles": [
"buyer"
],
"address": {
"region": "UKD3",
"locality": "Manchester",
"postalCode": "M20 4BX",
"countryName": "United Kingdom",
"streetAddress": "Wilmslow Road"
},
"details": {
"url": "https://www.christie.nhs.uk/",
"buyerProfile": "https://www.christie.nhs.uk/",
"classifications": [
{
"id": "BODY_PUBLIC",
"scheme": "TED_CA_TYPE",
"description": "Body governed by public law"
},
{
"id": "07",
"scheme": "COFOG",
"description": "Health"
}
]
},
"identifier": {
"legalName": "The Christie NHS Foundation Trust"
},
"contactPoint": {
"name": "Diane Sinclair",
"email": "diane.sinclair@nhs.net",
"telephone": "+44 7748624560"
}
},
{
"id": "GB-FTS-147363",
"name": "SYNLAB",
"roles": [
"supplier"
],
"address": {
"region": "UKI",
"locality": "London",
"postalCode": "SE1 1NA",
"countryName": "United Kingdom",
"streetAddress": "Francis House, 9 King's Head Yard, London."
},
"details": {
"url": "http://www.synlab.co.uk",
"scale": "sme"
},
"identifier": {
"id": "03216065",
"legalName": "SYNLAB"
},
"contactPoint": {
"email": "amy.davenport@synlab.co.uk"
}
},
{
"id": "GB-FTS-1661",
"name": "The High Court",
"roles": [
"reviewBody"
],
"address": {
"locality": "London",
"postalCode": "WC2A 2LL",
"countryName": "United Kingdom",
"streetAddress": "The Strand"
},
"details": {
"url": "https://www.judiciary.uk/courts-and-tribunals/high-court/"
},
"identifier": {
"legalName": "The High Court"
}
}
],
"language": "en",
"contracts": [
{
"id": "020560-2025-1",
"value": {
"amount": 200000000,
"currency": "GBP"
},
"status": "active",
"awardID": "020560-2025-1",
"dateSigned": "2025-05-12T00:00:00+01:00"
}
],
"description": "The proposed contract is to be let for an initial term of 180 months. There is also an option to extend the Contract by up to a further 60 months following the initial term.",
"initiationType": "tender"
}12 May 2025 · 020542-2025 · award, contract
{
"id": "020542-2025",
"tag": [
"award",
"contract"
],
"bids": {
"statistics": [
{
"id": "15",
"value": 1,
"measure": "bids",
"relatedLot": "1"
},
{
"id": "16",
"value": 1,
"measure": "electronicBids",
"relatedLot": "1"
}
]
},
"date": "2025-05-12T15:00:18+01:00",
"ocid": "ocds-h6vhtk-03a281",
"buyer": {
"id": "GB-FTS-40530",
"name": "The Christie NHS Foundation Trust"
},
"awards": [
{
"id": "020542-2025-1",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-147363",
"name": "SYNLAB"
}
],
"relatedLots": [
"1"
]
}
],
"tender": {
"id": "ocds-h6vhtk-03a281",
"lots": [
{
"id": "1",
"status": "cancelled",
"hasOptions": false,
"description": "The current pathology service provides routine and specialist pathology services with c100 dedicated staff on The Christie Hospital site. The service includes translational biomarker development and supports the Trust’s ambitious Research and Innovation (R&I) programme and clinical trials portfolio.<br/><br/>Demand for testing is increasing year on year reflecting the Trust’s oncology case load. The Trust sought a JV pathology partner who is able to deliver the Trust’s strategic ambitions, including accommodation of projected testing growth demand and flexible options for the development of facilities, estate, technology, and changes in clinical pathways.<br/><br/>Vision<br/>To provide a world leading comprehensive pathology service that supports timely and highquality<br/>delivery of patient care - regionally and nationally - and develops an internationally recognised workforce who, with academic and industry partners, deliver a pioneering<br/>programme of research and innovation.<br/><br/>Principles/Objectives<br/>The Future Pathology Service should reflect the following principles/objectives:<br/><br/>• Safe, effective, and responsive to the diversity of patient and clinical needs and offers the specialist and integrated pathology services needed to support a regional tertiary cancer centre.<br/>• Delivery of a sustainable future pathology workforce<br/>• alignment with the Trust’s Vision and Values and the objectives of Greater Manchester Cancer.<br/>• Commitment to working as part of Greater Manchester ICS in the delivery of the Core20PLUS5 programme to support the reduction of health inequalities at both national and system level.<br/>• Enabled by a strong digital infrastructure and capability. Adopting digital opportunity and technology advances to deliver more efficient and scalable pathology services.<br/>• A service model that considers The Trust’s local, regional national and international partnerships, including engagement with the Greater Manchester Pathology Network to<br/>explore opportunities to support system requirements.<br/>• Delivered through a partnership that has a strategy for profitable growth through expanding test repertoire and customer base.<br/>• Builds upon the Trust’s reputation as an international leader in research and innovation, which is further strengthened by being a partner in the Manchester Cancer Research Centre<br/>(MCRC) and Health Innovation Manchester.<br/>• A service with capital investment to provide best in class facilities.<br/>• A service that has education at its core.<br/><br/>The Future Operating Model for Pathology must include:<br/><br/>• An end-to-end comprehensive pathology service<br/>• Blood sciences including haematology, blood transfusion, clinical biochemistry and immunoassay<br/>• On-site essential services laboratory to support time critical and pathway critical services<br/>• Histopathology (including immunohistochemistry and receptor analysis)<br/>• Stem Cell Laboratory<br/>• Point-of-Care Testing<br/>• A future-proof design with activity growth in service expectation factored in – including expansion of on-site and off-site facilities to meet projected demand;<br/>• An agile approach that can respond to evolving technology and operational requirements and provide improvements to the Trust Pathology Estate;<br/>• Training, Development and Education, Research and Innovation<br/>• Positive workplace culture<br/>• IT infrastructure and digital enablement (including Digital Histopathology)<br/>• Best in class equipment and instrumentation",
"awardCriteria": {
"criteria": [
{
"name": "Clinical / Operational",
"type": "quality",
"description": "13"
},
{
"name": "Quality and Safety",
"type": "quality",
"description": "5"
},
{
"name": "Implementation",
"type": "quality",
"description": "4.8"
},
{
"name": "Future-proofing",
"type": "quality",
"description": "4.8"
},
{
"name": "Research & Innovation",
"type": "quality",
"description": "4.2"
},
{
"name": "Workforce",
"type": "quality",
"description": "8"
},
{
"name": "I&MT",
"type": "quality",
"description": "8"
},
{
"name": "Strategy, Risk & Governance",
"type": "quality",
"description": "7.2"
},
{
"name": "Social Value",
"type": "quality",
"description": "10"
},
{
"name": "Legal",
"type": "quality",
"description": "5"
},
{
"type": "price",
"description": "30"
}
]
}
}
],
"items": [
{
"id": "1",
"relatedLot": "1",
"deliveryAddresses": [
{
"region": "UKD3"
}
],
"additionalClassifications": [
{
"id": "85110000",
"scheme": "CPV",
"description": "Hospital and related services"
},
{
"id": "85111810",
"scheme": "CPV",
"description": "Blood analysis services"
}
]
}
],
"title": "Pathology Service Joint Venture",
"status": "complete",
"coveredBy": [
"GPA"
],
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"description": "The Trust has worked with a commercial partner in a joint venture (JV) arrangement to deliver a comprehensive pathology service for the last 10 years. Building on this knowledge and experience, the Trust was looking for a new partner that matches its ambitions.<br/>The initial term of the pathology service JVwill be for a period of fifteen (15) years with an option to extend by up to five (5) years.<br/>The Trust was looking for a partner that will;<br/>• Provide an exceptional, high-quality service that meets the specialist needs of a<br/>comprehensive cancer centre;<br/>• Provide investment for the provision of world class infrastructure;<br/>• Embrace the exciting opportunities presented with the co-location of a world leading<br/>oncology research centre; and<br/>• Provide expert guidance along with the creativity and drive to deliver a modern, thriving,<br/>truly exceptional pathology service for patients.",
"classification": {
"id": "85111800",
"scheme": "CPV",
"description": "Pathology services"
},
"procurementMethod": "selective",
"mainProcurementCategory": "services",
"procurementMethodDetails": "Competitive dialogue"
},
"parties": [
{
"id": "GB-FTS-40530",
"name": "The Christie NHS Foundation Trust",
"roles": [
"buyer"
],
"address": {
"region": "UKD3",
"locality": "Manchester",
"postalCode": "M20 4BX",
"countryName": "United Kingdom",
"streetAddress": "Wilmslow Road"
},
"details": {
"url": "https://www.christie.nhs.uk/",
"buyerProfile": "https://www.christie.nhs.uk/",
"classifications": [
{
"id": "BODY_PUBLIC",
"scheme": "TED_CA_TYPE",
"description": "Body governed by public law"
},
{
"id": "07",
"scheme": "COFOG",
"description": "Health"
}
]
},
"identifier": {
"legalName": "The Christie NHS Foundation Trust"
},
"contactPoint": {
"name": "Diane Sinclair",
"email": "diane.sinclair@nhs.net",
"telephone": "+44 7748624560"
}
},
{
"id": "GB-FTS-147363",
"name": "SYNLAB",
"roles": [
"supplier"
],
"address": {
"region": "UKI",
"locality": "London",
"postalCode": "SE1 1NA",
"countryName": "United Kingdom",
"streetAddress": "Francis House, 9 King's Head Yard, London."
},
"details": {
"url": "http://www.synlab.co.uk",
"scale": "sme"
},
"identifier": {
"id": "03216065",
"legalName": "SYNLAB"
},
"contactPoint": {
"email": "amy.davenport@synlab.co.uk"
}
},
{
"id": "GB-FTS-1661",
"name": "The High Court",
"roles": [
"reviewBody"
],
"address": {
"locality": "London",
"postalCode": "WC2A 2LL",
"countryName": "United Kingdom",
"streetAddress": "The Strand"
},
"details": {
"url": "https://www.judiciary.uk/courts-and-tribunals/high-court/"
},
"identifier": {
"legalName": "The High Court"
}
}
],
"language": "en",
"contracts": [
{
"id": "020542-2025-1",
"value": {
"amount": 200000000,
"currency": "GBP"
},
"status": "active",
"awardID": "020542-2025-1",
"dateSigned": "2025-05-12T00:00:00+01:00"
}
],
"description": "The proposed contract is to be let for an initial term of 180 months. There is also an option to extend the Contract by up to a further 60 months following the initial term.",
"initiationType": "tender"
}12 May 2025 · 020539-2025 · award, contract
{
"id": "020539-2025",
"tag": [
"award",
"contract"
],
"bids": {
"statistics": [
{
"id": "13",
"value": 1,
"measure": "bids",
"relatedLot": "1"
},
{
"id": "14",
"value": 1,
"measure": "electronicBids",
"relatedLot": "1"
}
]
},
"date": "2025-05-12T14:59:13+01:00",
"ocid": "ocds-h6vhtk-03a281",
"buyer": {
"id": "GB-FTS-40530",
"name": "The Christie NHS Foundation Trust"
},
"awards": [
{
"id": "020539-2025-1",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-147363",
"name": "SYNLAB"
}
],
"relatedLots": [
"1"
]
}
],
"tender": {
"id": "ocds-h6vhtk-03a281",
"lots": [
{
"id": "1",
"status": "cancelled",
"hasOptions": false,
"description": "The current pathology service provides routine and specialist pathology services with c100 dedicated staff on The Christie Hospital site. The service includes translational biomarker development and supports the Trust’s ambitious Research and Innovation (R&I) programme and clinical trials portfolio.<br/><br/>Demand for testing is increasing year on year reflecting the Trust’s oncology case load. The Trust sought a JV pathology partner who is able to deliver the Trust’s strategic ambitions, including accommodation of projected testing growth demand and flexible options for the development of facilities, estate, technology, and changes in clinical pathways.<br/><br/>Vision<br/>To provide a world leading comprehensive pathology service that supports timely and highquality<br/>delivery of patient care - regionally and nationally - and develops an internationally recognised workforce who, with academic and industry partners, deliver a pioneering<br/>programme of research and innovation.<br/><br/>Principles/Objectives<br/>The Future Pathology Service should reflect the following principles/objectives:<br/><br/>• Safe, effective, and responsive to the diversity of patient and clinical needs and offers the specialist and integrated pathology services needed to support a regional tertiary cancer centre.<br/>• Delivery of a sustainable future pathology workforce<br/>• alignment with the Trust’s Vision and Values and the objectives of Greater Manchester Cancer.<br/>• Commitment to working as part of Greater Manchester ICS in the delivery of the Core20PLUS5 programme to support the reduction of health inequalities at both national and system level.<br/>• Enabled by a strong digital infrastructure and capability. Adopting digital opportunity and technology advances to deliver more efficient and scalable pathology services.<br/>• A service model that considers The Trust’s local, regional national and international partnerships, including engagement with the Greater Manchester Pathology Network to<br/>explore opportunities to support system requirements.<br/>• Delivered through a partnership that has a strategy for profitable growth through expanding test repertoire and customer base.<br/>• Builds upon the Trust’s reputation as an international leader in research and innovation, which is further strengthened by being a partner in the Manchester Cancer Research Centre<br/>(MCRC) and Health Innovation Manchester.<br/>• A service with capital investment to provide best in class facilities.<br/>• A service that has education at its core.<br/><br/>The Future Operating Model for Pathology must include:<br/><br/>• An end-to-end comprehensive pathology service<br/>• Blood sciences including haematology, blood transfusion, clinical biochemistry and immunoassay<br/>• On-site essential services laboratory to support time critical and pathway critical services<br/>• Histopathology (including immunohistochemistry and receptor analysis)<br/>• Stem Cell Laboratory<br/>• Point-of-Care Testing<br/>• A future-proof design with activity growth in service expectation factored in – including expansion of on-site and off-site facilities to meet projected demand;<br/>• An agile approach that can respond to evolving technology and operational requirements and provide improvements to the Trust Pathology Estate;<br/>• Training, Development and Education, Research and Innovation<br/>• Positive workplace culture<br/>• IT infrastructure and digital enablement (including Digital Histopathology)<br/>• Best in class equipment and instrumentation",
"awardCriteria": {
"criteria": [
{
"name": "Clinical / Operational",
"type": "quality",
"description": "13"
},
{
"name": "Quality and Safety",
"type": "quality",
"description": "5"
},
{
"name": "Implementation",
"type": "quality",
"description": "4.8"
},
{
"name": "Future-proofing",
"type": "quality",
"description": "4.8"
},
{
"name": "Research & Innovation",
"type": "quality",
"description": "4.2"
},
{
"name": "Workforce",
"type": "quality",
"description": "8"
},
{
"name": "I&MT",
"type": "quality",
"description": "8"
},
{
"name": "Strategy, Risk & Governance",
"type": "quality",
"description": "7.2"
},
{
"name": "Social Value",
"type": "quality",
"description": "10"
},
{
"name": "Legal",
"type": "quality",
"description": "5"
},
{
"type": "price",
"description": "30"
}
]
}
}
],
"items": [
{
"id": "1",
"relatedLot": "1",
"deliveryAddresses": [
{
"region": "UKD3"
}
],
"additionalClassifications": [
{
"id": "85110000",
"scheme": "CPV",
"description": "Hospital and related services"
},
{
"id": "85111810",
"scheme": "CPV",
"description": "Blood analysis services"
}
]
}
],
"title": "Pathology Service Joint Venture",
"status": "complete",
"coveredBy": [
"GPA"
],
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"description": "The Trust has worked with a commercial partner in a joint venture (JV) arrangement to deliver a comprehensive pathology service for the last 10 years. Building on this knowledge and experience, the Trust was looking for a new partner that matches its ambitions.<br/>The initial term of the pathology service JVwill be for a period of fifteen (15) years with an option to extend by up to five (5) years.<br/>The Trust was looking for a partner that will;<br/>• Provide an exceptional, high-quality service that meets the specialist needs of a<br/>comprehensive cancer centre;<br/>• Provide investment for the provision of world class infrastructure;<br/>• Embrace the exciting opportunities presented with the co-location of a world leading<br/>oncology research centre; and<br/>• Provide expert guidance along with the creativity and drive to deliver a modern, thriving,<br/>truly exceptional pathology service for patients.",
"classification": {
"id": "85111800",
"scheme": "CPV",
"description": "Pathology services"
},
"procurementMethod": "selective",
"mainProcurementCategory": "services",
"procurementMethodDetails": "Competitive dialogue"
},
"parties": [
{
"id": "GB-FTS-40530",
"name": "The Christie NHS Foundation Trust",
"roles": [
"buyer"
],
"address": {
"region": "UKD3",
"locality": "Manchester",
"postalCode": "M20 4BX",
"countryName": "United Kingdom",
"streetAddress": "Wilmslow Road"
},
"details": {
"url": "https://www.christie.nhs.uk/",
"buyerProfile": "https://www.christie.nhs.uk/",
"classifications": [
{
"id": "BODY_PUBLIC",
"scheme": "TED_CA_TYPE",
"description": "Body governed by public law"
},
{
"id": "07",
"scheme": "COFOG",
"description": "Health"
}
]
},
"identifier": {
"legalName": "The Christie NHS Foundation Trust"
},
"contactPoint": {
"name": "Diane Sinclair",
"email": "diane.sinclair@nhs.net",
"telephone": "+44 7748624560"
}
},
{
"id": "GB-FTS-147363",
"name": "SYNLAB",
"roles": [
"supplier"
],
"address": {
"region": "UKI",
"locality": "London",
"postalCode": "SE1 1NA",
"countryName": "United Kingdom",
"streetAddress": "Francis House, 9 King's Head Yard, London."
},
"details": {
"url": "http://www.synlab.co.uk",
"scale": "sme"
},
"identifier": {
"id": "03216065",
"legalName": "SYNLAB"
},
"contactPoint": {
"email": "amy.davenport@synlab.co.uk"
}
},
{
"id": "GB-FTS-1661",
"name": "The High Court",
"roles": [
"reviewBody"
],
"address": {
"locality": "London",
"postalCode": "WC2A 2LL",
"countryName": "United Kingdom",
"streetAddress": "The Strand"
},
"details": {
"url": "https://www.judiciary.uk/courts-and-tribunals/high-court/"
},
"identifier": {
"legalName": "The High Court"
}
}
],
"language": "en",
"contracts": [
{
"id": "020539-2025-1",
"value": {
"amount": 200000000,
"currency": "GBP"
},
"status": "active",
"awardID": "020539-2025-1",
"dateSigned": "2025-05-12T00:00:00+01:00"
}
],
"description": "The proposed contract is to be let for an initial term of 180 months. There is also an option to extend the Contract by up to a further 60 months following the initial term.",
"initiationType": "tender"
}12 May 2025 · 020538-2025 · award, contract
{
"id": "020538-2025",
"tag": [
"award",
"contract"
],
"bids": {
"statistics": [
{
"id": "11",
"value": 1,
"measure": "bids",
"relatedLot": "1"
},
{
"id": "12",
"value": 1,
"measure": "electronicBids",
"relatedLot": "1"
}
]
},
"date": "2025-05-12T14:58:26+01:00",
"ocid": "ocds-h6vhtk-03a281",
"buyer": {
"id": "GB-FTS-40530",
"name": "The Christie NHS Foundation Trust"
},
"awards": [
{
"id": "020538-2025-1",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-147363",
"name": "SYNLAB"
}
],
"relatedLots": [
"1"
]
}
],
"tender": {
"id": "ocds-h6vhtk-03a281",
"lots": [
{
"id": "1",
"status": "cancelled",
"hasOptions": false,
"description": "The current pathology service provides routine and specialist pathology services with c100 dedicated staff on The Christie Hospital site. The service includes translational biomarker development and supports the Trust’s ambitious Research and Innovation (R&I) programme and clinical trials portfolio.<br/><br/>Demand for testing is increasing year on year reflecting the Trust’s oncology case load. The Trust sought a JV pathology partner who is able to deliver the Trust’s strategic ambitions, including accommodation of projected testing growth demand and flexible options for the development of facilities, estate, technology, and changes in clinical pathways.<br/><br/>Vision<br/>To provide a world leading comprehensive pathology service that supports timely and highquality<br/>delivery of patient care - regionally and nationally - and develops an internationally recognised workforce who, with academic and industry partners, deliver a pioneering<br/>programme of research and innovation.<br/><br/>Principles/Objectives<br/>The Future Pathology Service should reflect the following principles/objectives:<br/><br/>• Safe, effective, and responsive to the diversity of patient and clinical needs and offers the specialist and integrated pathology services needed to support a regional tertiary cancer centre.<br/>• Delivery of a sustainable future pathology workforce<br/>• alignment with the Trust’s Vision and Values and the objectives of Greater Manchester Cancer.<br/>• Commitment to working as part of Greater Manchester ICS in the delivery of the Core20PLUS5 programme to support the reduction of health inequalities at both national and system level.<br/>• Enabled by a strong digital infrastructure and capability. Adopting digital opportunity and technology advances to deliver more efficient and scalable pathology services.<br/>• A service model that considers The Trust’s local, regional national and international partnerships, including engagement with the Greater Manchester Pathology Network to<br/>explore opportunities to support system requirements.<br/>• Delivered through a partnership that has a strategy for profitable growth through expanding test repertoire and customer base.<br/>• Builds upon the Trust’s reputation as an international leader in research and innovation, which is further strengthened by being a partner in the Manchester Cancer Research Centre<br/>(MCRC) and Health Innovation Manchester.<br/>• A service with capital investment to provide best in class facilities.<br/>• A service that has education at its core.<br/><br/>The Future Operating Model for Pathology must include:<br/><br/>• An end-to-end comprehensive pathology service<br/>• Blood sciences including haematology, blood transfusion, clinical biochemistry and immunoassay<br/>• On-site essential services laboratory to support time critical and pathway critical services<br/>• Histopathology (including immunohistochemistry and receptor analysis)<br/>• Stem Cell Laboratory<br/>• Point-of-Care Testing<br/>• A future-proof design with activity growth in service expectation factored in – including expansion of on-site and off-site facilities to meet projected demand;<br/>• An agile approach that can respond to evolving technology and operational requirements and provide improvements to the Trust Pathology Estate;<br/>• Training, Development and Education, Research and Innovation<br/>• Positive workplace culture<br/>• IT infrastructure and digital enablement (including Digital Histopathology)<br/>• Best in class equipment and instrumentation",
"awardCriteria": {
"criteria": [
{
"name": "Clinical / Operational",
"type": "quality",
"description": "13"
},
{
"name": "Quality and Safety",
"type": "quality",
"description": "5"
},
{
"name": "Implementation",
"type": "quality",
"description": "4.8"
},
{
"name": "Future-proofing",
"type": "quality",
"description": "4.8"
},
{
"name": "Research & Innovation",
"type": "quality",
"description": "4.2"
},
{
"name": "Workforce",
"type": "quality",
"description": "8"
},
{
"name": "I&MT",
"type": "quality",
"description": "8"
},
{
"name": "Strategy, Risk & Governance",
"type": "quality",
"description": "7.2"
},
{
"name": "Social Value",
"type": "quality",
"description": "10"
},
{
"name": "Legal",
"type": "quality",
"description": "5"
},
{
"type": "price",
"description": "30"
}
]
}
}
],
"items": [
{
"id": "1",
"relatedLot": "1",
"deliveryAddresses": [
{
"region": "UKD3"
}
],
"additionalClassifications": [
{
"id": "85110000",
"scheme": "CPV",
"description": "Hospital and related services"
},
{
"id": "85111810",
"scheme": "CPV",
"description": "Blood analysis services"
}
]
}
],
"title": "Pathology Service Joint Venture",
"status": "complete",
"coveredBy": [
"GPA"
],
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"description": "The Trust has worked with a commercial partner in a joint venture (JV) arrangement to deliver a comprehensive pathology service for the last 10 years. Building on this knowledge and experience, the Trust was looking for a new partner that matches its ambitions.<br/>The initial term of the pathology service JVwill be for a period of fifteen (15) years with an option to extend by up to five (5) years.<br/>The Trust was looking for a partner that will;<br/>• Provide an exceptional, high-quality service that meets the specialist needs of a<br/>comprehensive cancer centre;<br/>• Provide investment for the provision of world class infrastructure;<br/>• Embrace the exciting opportunities presented with the co-location of a world leading<br/>oncology research centre; and<br/>• Provide expert guidance along with the creativity and drive to deliver a modern, thriving,<br/>truly exceptional pathology service for patients.",
"classification": {
"id": "85111800",
"scheme": "CPV",
"description": "Pathology services"
},
"procurementMethod": "selective",
"mainProcurementCategory": "services",
"procurementMethodDetails": "Competitive dialogue"
},
"parties": [
{
"id": "GB-FTS-40530",
"name": "The Christie NHS Foundation Trust",
"roles": [
"buyer"
],
"address": {
"region": "UKD3",
"locality": "Manchester",
"postalCode": "M20 4BX",
"countryName": "United Kingdom",
"streetAddress": "Wilmslow Road"
},
"details": {
"url": "https://www.christie.nhs.uk/",
"buyerProfile": "https://www.christie.nhs.uk/",
"classifications": [
{
"id": "BODY_PUBLIC",
"scheme": "TED_CA_TYPE",
"description": "Body governed by public law"
},
{
"id": "07",
"scheme": "COFOG",
"description": "Health"
}
]
},
"identifier": {
"legalName": "The Christie NHS Foundation Trust"
},
"contactPoint": {
"name": "Diane Sinclair",
"email": "diane.sinclair@nhs.net",
"telephone": "+44 7748624560"
}
},
{
"id": "GB-FTS-147363",
"name": "SYNLAB",
"roles": [
"supplier"
],
"address": {
"region": "UKI",
"locality": "London",
"postalCode": "SE1 1NA",
"countryName": "United Kingdom",
"streetAddress": "Francis House, 9 King's Head Yard, London."
},
"details": {
"url": "http://www.synlab.co.uk",
"scale": "sme"
},
"identifier": {
"id": "03216065",
"legalName": "SYNLAB"
},
"contactPoint": {
"email": "amy.davenport@synlab.co.uk"
}
},
{
"id": "GB-FTS-1661",
"name": "The High Court",
"roles": [
"reviewBody"
],
"address": {
"locality": "London",
"postalCode": "WC2A 2LL",
"countryName": "United Kingdom",
"streetAddress": "The Strand"
},
"details": {
"url": "https://www.judiciary.uk/courts-and-tribunals/high-court/"
},
"identifier": {
"legalName": "The High Court"
}
}
],
"language": "en",
"contracts": [
{
"id": "020538-2025-1",
"value": {
"amount": 200000000,
"currency": "GBP"
},
"status": "active",
"awardID": "020538-2025-1",
"dateSigned": "2025-05-12T00:00:00+01:00"
}
],
"description": "The proposed contract is to be let for an initial term of 180 months. There is also an option to extend the Contract by up to a further 60 months following the initial term.",
"initiationType": "tender"
}26 Oct 2023 · 031674-2023 · tender
{
"id": "031674-2023",
"tag": [
"tender"
],
"date": "2023-10-26T16:22:43+01:00",
"ocid": "ocds-h6vhtk-03a281",
"buyer": {
"id": "GB-FTS-40530",
"name": "The Christie NHS Foundation Trust"
},
"tender": {
"id": "ocds-h6vhtk-03a281",
"lots": [
{
"id": "1",
"value": {
"amount": 240000000,
"currency": "GBP"
},
"status": "active",
"renewal": {
"description": "The proposed contract is to be let for an initial term of 180 months. There is also an option to extend the Contract by up to a further 60 months following the initial term."
},
"hasOptions": false,
"hasRenewal": true,
"description": "The current pathology service provides routine and specialist pathology services with c100 dedicated staff on The Christie Hospital site. The service includes translational biomarker development and supports the Trust’s ambitious Research and Innovation (R&I) programme and clinical trials portfolio. <br/><br/>Demand for testing is increasing year on year reflecting the Trust’s oncology case load. <br/>The Trust seeks a JV pathology partner who is able to deliver the Trust’s strategic ambitions, including accommodation of projected testing growth demand and flexible options for the development of facilities, estate, technology, and changes in clinical pathways. <br/><br/>Vision<br/><br/>To provide a world leading comprehensive pathology service that supports timely and high-quality delivery of patient care - regionally and nationally - and develops an internationally recognised workforce who, with academic and industry partners, deliver a pioneering programme of research and innovation.<br/><br/>Principles/Objectives<br/><br/>The Future Pathology Service should reflect the following principles/objectives:<br/><br/>•\tSafe, effective, and responsive to the diversity of patient and clinical needs and offers the specialist and integrated pathology services needed to support a regional tertiary cancer centre.<br/>•\tDelivery of a sustainable future pathology workforce<br/>•\talignment with the Trust’s Vision and Values and the objectives of Greater Manchester Cancer.<br/>•\tCommitment to working as part of Greater Manchester ICS in the delivery of the Core20PLUS5 programme to support the reduction of health inequalities at both national and system level.<br/>•\tEnabled by a strong digital infrastructure and capability. Adopting digital opportunity and technology advances to deliver more efficient and scalable pathology services.<br/>•\tA service model that considers The Trust’s local, regional national and international partnerships, including engagement with the Greater Manchester Pathology Network to explore opportunities to support system requirements.<br/>•\tDelivered through a partnership that has a strategy for profitable growth through expanding test repertoire and customer base.<br/>•\tBuilds upon the Trust’s reputation as an international leader in research and innovation, which is further strengthened by being a partner in the Manchester Cancer Research Centre (MCRC) and Health Innovation Manchester.<br/>•\tA service with capital investment to provide best in class facilities.<br/>•\tA service that has education at its core.<br/><br/>The Future Operating Model for Pathology must include:<br/><br/>•\tAn end-to-end comprehensive pathology service<br/>•\tBlood sciences including haematology, blood transfusion, clinical biochemistry and immunoassay<br/>•\tOn-site essential services laboratory to support time critical and pathway critical services<br/>•\tHistopathology (including immunohistochemistry and receptor analysis)<br/>•\tStem Cell Laboratory<br/>•\tPoint-of-Care Testing <br/>•\tA future-proof design with activity growth in service expectation factored in – including expansion of on-site and off-site facilities to meet projected demand;<br/>•\tAn agile approach that can respond to evolving technology and operational requirements and provide improvements to the Trust Pathology Estate; <br/>•\tTraining, Development and Education, Research and Innovation <br/>•\tPositive workplace culture<br/>•\tIT infrastructure and digital enablement (including Digital Histopathology)<br/>•\tBest in class equipment and instrumentation<br/><br/>Further information and details about the requirements and scope of the procurement are set out in the Statement of Requirements and supporting information which will be available as part of the procurement documents at https://health-family.force.com/s/Welcome. Additional information: The estimated value in II.2.6 is based on the existing annual turnover of the JV over the lifetime of the contract.",
"secondStage": {
"maximumCandidates": 3,
"minimumCandidates": 3
},
"contractPeriod": {
"durationInDays": 7200
},
"submissionTerms": {
"variantPolicy": "notAllowed"
},
"selectionCriteria": {
"description": "As specified in the SQ/ITPD documentation"
}
}
],
"items": [
{
"id": "1",
"relatedLot": "1",
"deliveryAddresses": [
{
"region": "UKD3"
}
],
"additionalClassifications": [
{
"id": "85110000",
"scheme": "CPV",
"description": "Hospital and related services"
},
{
"id": "85111810",
"scheme": "CPV",
"description": "Blood analysis services"
}
]
}
],
"title": "Pathology Service Joint Venture",
"status": "active",
"coveredBy": [
"GPA"
],
"documents": [
{
"id": "economic",
"documentType": "economicSelectionCriteria"
},
{
"id": "technical",
"documentType": "technicalSelectionCriteria"
}
],
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"description": "The Trust has worked with a commercial partner in a joint venture (JV) arrangement to deliver a comprehensive pathology service for the last 10 years. Building on this knowledge and experience, the Trust is looking for a new partner that matches its ambitions. <br/><br/>The initial term of the pathology service JV is expected to be for a period of fifteen (15) years with an option to extend by up to five (5) years.<br/><br/>The Trust is looking for a partner that will;<br/><br/>•\tProvide an exceptional, high-quality service that meets the specialist needs of a comprehensive cancer centre;<br/>•\tProvide investment for the provision of world class infrastructure;<br/>•\tEmbrace the exciting opportunities presented with the co-location of a world leading oncology research centre; and<br/>•\tProvide expert guidance along with the creativity and drive to deliver a modern, thriving, truly exceptional pathology service for patients.",
"secondStage": {
"invitationDate": "2023-12-11T00:00:00Z",
"successiveReduction": true
},
"tenderPeriod": {
"endDate": "2023-11-27T16:00:00Z"
},
"communication": {
"atypicalToolUrl": "https://health-family.force.com/s/Welcome"
},
"hasRecurrence": false,
"classification": {
"id": "85111800",
"scheme": "CPV",
"description": "Pathology services"
},
"submissionTerms": {
"languages": [
"en"
],
"bidValidityPeriod": {
"durationInDays": 360
}
},
"submissionMethod": [
"electronicSubmission",
"written"
],
"procurementMethod": "selective",
"selectionCriteria": {
"criteria": [
{
"type": "technical",
"description": "Execution of the service is reserved to a particular profession"
}
]
},
"mainProcurementCategory": "services",
"submissionMethodDetails": "https://health-family.force.com/s/Welcome",
"procurementMethodDetails": "Competitive dialogue"
},
"parties": [
{
"id": "GB-FTS-40530",
"name": "The Christie NHS Foundation Trust",
"roles": [
"buyer"
],
"address": {
"region": "UKD3",
"locality": "Manchester",
"postalCode": "M20 4BX",
"countryName": "United Kingdom",
"streetAddress": "Wilmslow Road"
},
"details": {
"url": "https://www.christie.nhs.uk/",
"buyerProfile": "https://www.christie.nhs.uk/",
"classifications": [
{
"id": "BODY_PUBLIC",
"scheme": "TED_CA_TYPE",
"description": "Body governed by public law"
},
{
"id": "07",
"scheme": "COFOG",
"description": "Health"
}
]
},
"identifier": {
"legalName": "The Christie NHS Foundation Trust"
},
"contactPoint": {
"url": "https://health-family.force.com/s/Welcome",
"name": "Diane Sinclair",
"email": "Diane.Sinclair@nhs.net",
"telephone": "+44 7748624560"
}
},
{
"id": "GB-FTS-1661",
"name": "The High Court",
"roles": [
"reviewBody"
],
"address": {
"locality": "London",
"postalCode": "WC2A 2LL",
"countryName": "United Kingdom",
"streetAddress": "The Strand"
},
"details": {
"url": "https://www.judiciary.uk/courts-and-tribunals/high-court/"
},
"identifier": {
"legalName": "The High Court"
}
}
],
"language": "en",
"initiationType": "tender"
}6 Feb 2023 · 003612-2023 · tenderUpdate
{
"id": "003612-2023",
"tag": [
"tenderUpdate"
],
"date": "2023-02-06T15:42:35Z",
"ocid": "ocds-h6vhtk-03a281",
"buyer": {
"id": "GB-FTS-35200",
"name": "The Christie NHS Foundation Trust"
},
"tender": {
"id": "DN652962",
"title": "Pathology Services Partnership",
"amendments": [
{
"id": "1",
"unstructuredChanges": [
{
"where": {
"label": "Description of the procurement",
"section": "II.2.4"
},
"newValue": {
"text": "The new partnership will need to provide the following:\n•\tA Blood Sciences Essential Services Laboratory (ESL) to achieve rapid turnaround time necessary for clinical pathways and patient flow, ideally on site to facilitate tight turnaround times, and;\n•\tCore Clinical Biochemistry, immunoassay and haematology testing within the ESL to be fully automated, enabling rapid turnaround of test results through pathology workflow efficiencies.\n•\tHistopathology\n•\tMolecular Diagnostics\n•\tBreast and Gastro-oesophageal Tumour Receptors\n•\tBereavement and Mortuary.\nThe Blood Sciences laboratory includes Clinical Biochemistry, Haematology, Blood Transfusion and Stem Cell.\nResearch and innovation including Blood Sciences Translational Biomarker lab and, Academic Histopathology.\nIT infrastructure and digital capability. LIMS infrastructure and integration of Digital Pathology and opportunities to apply Artificial Intelligence/Machine Learning to support diagnostic processes/predictive algorithms across Histopathology and Blood Sciences. Business Intelligence capability to optimise performance monitoring and service workflow/workforce, and demand/capacity modelling.\nExploration of Microbiology and Virology services (currently outsourced)."
},
"oldValue": {
"text": "The new partnership will need to provide the following:\n•\tA Blood Sciences Essential Services Laboratory (ESL) to achieve rapid turnaround time necessary for clinical pathways and patient flow, ideally on site to facilitate tight turnaround times, and;\n•\tCore Clinical Biochemistry, immunoassay and haematology testing within the ESL to be fully automated, enabling rapid turnaround of test results through pathology workflow efficiencies."
}
}
]
}
],
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"description": "Pathology is an essential clinical service, vital to the delivery of efficient and effective\nhealthcare by preventing, diagnosing, treating and monitoring diseases to keep people as\nhealthy as possible.\nBuilding on its knowledge and experience, and with the current Joint Venture contract\ncoming to an end in 2024, The Christie is looking for a commercial partner who matches its\nambitions; who can provide an exceptional, high-quality service that meets the specialist\nneeds of a comprehensive cancer centre; who can provide investment for the provision of\nworld class infrastructure; who will embrace the exciting opportunities presented with the colocation of a world leading oncology research centre and; who will provide expert guidance\nalong with the creativity and drive to deliver a modern, thriving, truly exceptional pathology\nservice for our patients.",
"classification": {
"id": "85111000",
"scheme": "CPV",
"description": "Hospital services"
},
"mainProcurementCategory": "services"
},
"parties": [
{
"id": "GB-FTS-35200",
"name": "The Christie NHS Foundation Trust",
"roles": [
"buyer"
],
"address": {
"region": "UKD3",
"locality": "Manchester",
"postalCode": "M20 4BX",
"countryName": "United Kingdom",
"streetAddress": "The Christie NHS Foundation Trust, Wilmslow Road"
},
"details": {
"url": "https://www.christie.nhs.uk",
"buyerProfile": "https://www.christie.nhs.uk"
},
"identifier": {
"legalName": "The Christie NHS Foundation Trust"
},
"contactPoint": {
"name": "Ms Diane Sinclair",
"email": "Diane.Sinclair@nhs.net",
"telephone": "+44 7748624560"
}
}
],
"language": "en",
"initiationType": "tender"
}2 Feb 2023 · 003320-2023 · planning
{
"id": "003320-2023",
"tag": [
"planning"
],
"date": "2023-02-02T16:22:57Z",
"ocid": "ocds-h6vhtk-03a281",
"buyer": {
"id": "GB-FTS-35200",
"name": "The Christie NHS Foundation Trust"
},
"tender": {
"id": "DN652962",
"lots": [
{
"id": "1",
"status": "planned",
"description": "Vision\nTo provide a world leading comprehensive pathology service that supports timely and high-quality delivery of patient care - regionally and nationally - and develops an internationally recognised workforce who, with academic and industry partners, deliver a pioneering programme of research and innovation.\nPrinciples/Objectives\nThe new Christie pathology service(s) should include the following:\n•\t Create an advanced integrated cancer diagnosis and research pathology facility that draws on the excellence of its partners in advancing the latest techniques for both research and service\n•\t Be leaders in academic oncology pathology and research with close academic relationships with the CRUK, NIHR, Paterson Biomarker Centre and the MCRC (University of Manchester).\n•\t Create/attract sufficient funding to deliver new/refurbished facilities recognising the limitations of the current estate places on the ability of Blood Science and Histopathology to expand or improve services;\n•\t Maintain turn-around times (TAT) and other basic service requirements for Blood Sciences and therefore to retain these services on-site;\n•\t Supports appropriate Histopathology facilities and expertise on site with both current surgical activity and future ambitions, and ensure that our world-leading oncology Histopathology expertise is not diluted;\n•\tWhere possible and appropriate, engage in the further consolidation of pathology services across GM;\n•\tExploit digital networking solutions and maximise digital technologies in the pursuit of high quality, innovative, efficient services which reduce variability of performance across the region;\n•\tExpand pathology services into the private healthcare sector;\n•\tEnsure a highly skilled and motivated workforce across all departments, with a clear education programme for continual learning and knowledge sharing;\n•\tAny proposed investment or collaboration with a commercial partner and consequent development of commercial opportunities should ultimately have a positive financial impact on the Christie and improve the Trust’s ongoing financial sustainability\nBroad service level scope\nThe new partnership will need to provide the following:\n•\tA Blood Sciences Essential Services Laboratory (ESL) to achieve rapid turnaround time necessary for clinical pathways and patient flow, ideally on site to facilitate tight turnaround times, and;\n•\tCore Clinical Biochemistry, immunoassay and haematology testing within the ESL to be fully automated, enabling rapid turnaround of test results through pathology workflow efficiencies. Additional information: The Christie NHS Foundation Trust is issuing this PIN to alert the market to a future competitive tender opportunity.\nThe Christie NHS Foundation Trust is utilising the ProContract procurement tendering portal for interested parties to express their interest.\nIt is important to note that this PIN is not a call for competition and as such potential providers will need to express interest in any future tender opportunity once a contract notice is published on the Find Tender Service (FTS) and on Contracts Finder."
}
],
"items": [
{
"id": "1",
"relatedLot": "1",
"deliveryAddresses": [
{
"region": "UKD"
}
],
"additionalClassifications": [
{
"id": "85110000",
"scheme": "CPV",
"description": "Hospital and related services"
}
]
}
],
"title": "Pathology Services Partnership",
"status": "planned",
"coveredBy": [
"GPA"
],
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"description": "Pathology is an essential clinical service, vital to the delivery of efficient and effective healthcare by preventing, diagnosing, treating and monitoring diseases to keep people as healthy as possible.\nBuilding on its knowledge and experience, and with the current Joint Venture contract coming to an end in 2024, The Christie is looking for a commercial partner who matches its ambitions; who can provide an exceptional, high-quality service that meets the specialist needs of a comprehensive cancer centre; who can provide investment for the provision of world class infrastructure; who will embrace the exciting opportunities presented with the co-location of a world leading oncology research centre and; who will provide expert guidance along with the creativity and drive to deliver a modern, thriving, truly exceptional pathology service for our patients.",
"communication": {
"futureNoticeDate": "2023-05-01T00:00:00+01:00"
},
"classification": {
"id": "85111800",
"scheme": "CPV",
"description": "Pathology services"
},
"mainProcurementCategory": "services"
},
"parties": [
{
"id": "GB-FTS-35200",
"name": "The Christie NHS Foundation Trust",
"roles": [
"buyer"
],
"address": {
"region": "UKD3",
"locality": "Manchester",
"postalCode": "M20 4BX",
"countryName": "United Kingdom",
"streetAddress": "The Christie NHS Foundation Trust, Wilmslow Road"
},
"details": {
"url": "https://www.christie.nhs.uk",
"buyerProfile": "https://www.christie.nhs.uk",
"classifications": [
{
"id": "BODY_PUBLIC",
"scheme": "TED_CA_TYPE",
"description": "Body governed by public law"
},
{
"id": "07",
"scheme": "COFOG",
"description": "Health"
}
]
},
"identifier": {
"legalName": "The Christie NHS Foundation Trust"
},
"contactPoint": {
"name": "Ms Diane Sinclair",
"email": "Diane.Sinclair@nhs.net",
"telephone": "+44 7748624560"
}
}
],
"language": "en",
"initiationType": "tender"
}